ĐÁNH GIÁ TÁC ĐỘNG CỦA TRÍ TUỆ NHÂN TẠO ĐA PHƯƠNG THỨC ĐỐI VỚI QUY TRÌNH CHẨN ĐOÁN UNG THƯ VÒM MŨI HỌNG TẠI VIỆT NAM
Main Article Content
Abstract
Nasopharyngeal carcinoma in Vietnam is still commonly diagnosed at advanced stages because early symptoms are subtle and clinically fragmented information often exists across endoscopy, cross-sectional imaging, and biomarkers. This study evaluated the impact of multimodal artificial intelligence integrating endoscopy, CT/MRI, and EBV-DNA on diagnostic performance, clinical decision-making, and implementation feasibility. A mixed-method design was used, combining a practice survey, retrospective-prospective analysis of 256 patients, and comparison between conventional and AI-assisted diagnostic pathways. Multimodal AI improved early-stage detection from 28.9% to 46.5% (p<0.001), reduced missed small lesions from 18.7% to 6.2% (p<0.001), shortened diagnostic time from 28.4 to 16.7 days (p<0.001), and increased correct biopsy indication from 72.3% to 88.7%. The multimodal model achieved sensitivity of 96.5%, specificity of 90.2%, accuracy of 93.8%, and an AUC of 0.97. AI changed diagnostic decisions in 22.3% of cases and increased physician agreement for biopsy indication from 68.5% to 87.9%. Multimodal AI therefore improves both technical performance and real-world diagnostic workflow for nasopharyngeal carcinoma in Vietnam.
Keywords
nasopharyngeal carcinoma, multimodal artificial intelligence, endoscopy, MRI, EBV-DNA, early diagnosis.
Article Details
References
2. Wong KC, và cs. Nasopharyngeal carcinoma: An evolving paradigm. Nature Reviews Clinical Oncology. 2021.
3. Bossi P, và cs. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2021.
4. Chen YP, và cs. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. Journal of Clinical Oncology. 2021.
5. Liu YP, và cs. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology. 2021.
6. Khai Q Luu, và cs. Ứng dụng AI trong lĩnh vực điều trị ung thư vòm họng: Tổng quan tài liệu hệ thống. VNU-UET. 2026.
7. Chan KA, và cs. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. New England Journal of Medicine. 2017.
8. Lam WKJ, và cs. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. PNAS. 2018.
9. Li T, và cs. Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer. New England Journal of Medicine. 2023.
10. Xu J, và cs. A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform. British Journal of Cancer. 2024.
11. Zhang S, và cs. Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. Cancer Cell. 2025.
12. Lam WJ, và cs. Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. Journal of the National Cancer Institute. 2023.
13. Jiang C, và cs. CRISPR Cas12a-mediated amplification-free digital DNA assay improves the diagnosis and surveillance of nasopharyngeal carcinoma. Biosensors and Bioelectronics. 2023.
14. Sun K, và cs. Tumor-educated platelet miR-18a-3p as a novel liquid-biopsy biomarker for early diagnosis and chemotherapy efficacy monitoring in nasopharyngeal carcinoma. Frontiers in Oncology. 2021.
15. Lee VHF, và cs. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings. Lancet Oncology. 2022.
16. Jin E, và cs. Collaborative breakthroughs in precision diagnosis and treatment of nasopharyngeal cancer: biomarker-driven screening and endoscopic minimally invasive surgery reshape the new paradigm of early intervention. Oncology Reports. 2026.